Model Image 23

ACCESSIBILITY

Not an actual patient.

The Site is brought to you by Sinclair Pharma Ltd (Sinclair). Our registered office is 30-32 Whitfield Street, Whitfield Court, London, W1T 2RQ with company registration number 03816616.

Sinclair recognises the importance of providing a website that is accessible to all user groups including people with disabilities such as blindness and low vision, deafness and hearing loss, learning disabilities, cognitive limitations, limited movement, speech disabilities, photosensitivity and combinations of these.

Sinclair has designed the Site with accessibility in mind, following the guidelines laid down by the W3C Web Accessibility Initiative (WAI).

Web Content Accessibility Guidelines (WCAG) 2.0 covers a wide range of recommendations for making web content more accessible to a wider range of people with disabilities and will also often make web content more usable to users in general.

The 12 accessibility guidelines are:

Provide text alternatives for non-text content.
Provide captions and alternatives for audio and video content.
Make content adaptable; and make it available to assistive technologies.
Use sufficient contrast to make things easy to see and hear.
Make all functionality keyboard accessible.
Give users enough time to read and use content.
Do not use content that causes seizures.
Help users navigate and find content.
Make text readable and understandable.
Make content appear and operate in predictable ways.
Help users avoid and correct mistakes.
Maximize compatibility with current and future technologies.
There are three levels of conformance to the accessibility guidelines: A (lowest), AA, and AAA (highest) and our aim is to conform to AA Level. However these are guidelines only and in some instances it is not practical to conform exactly to all checkpoints. If you have any queries about the accessibility of this website please contact enquiries@sinclairpharma.com

INDICATION:

The EU approved intended use is: Ellansé (a Poly-ɛ-caprolactone-based dermal filler) is an injectable implant, indicated for subdermal implantation in the face for the lasting correction of wrinkles and facial aging signs or conditions.

INDICATION:

The EU approved intended use is: Ellansé (a Poly-ɛ-caprolactone-based dermal filler) is an injectable implant, indicated for subdermal implantation in the face for the lasting correction of wrinkles and facial aging signs or conditions.

Important Safety Considerations:

Like all procedures of this type there is a possibility of adverse events, although not everybody experiences them. These adverse events include but are not limited to infection, minimal acute inflammatory tissue reaction (redness, swelling, rash, oedema, erythema, lumps/nodules etc.), pain (which may be temporary or persistent in nature), transient haematoma or bruising.

Other potential adverse events include

- Injection related reactions, include itching, discoloration or tenderness may occur at the site of the injection. These usually resolve spontaneously within several days after the injection.

- As with any implant material possible adverse reactions that may occur include, but are not limited to the following: hypersensitivity, allergic reactions, inflammation, infection, fistula formation, haematoma, seroma, extrusion, induration formation, inadequate healing, skin discoloration, oedema, contusions/bruises, ecchymosis, inadequate or excessive augmentation, loss of correction, interference with local circulation if injected into a blood vessel resulting in vessel laceration, occlusion, embolism, infarction, and abscess at implant site which may result in induration and/or scar formation.

- Rare but serious adverse events associated with the intravascular injection of soft tissue fillers in the face have been reported and include temporary or permanent vision impairment, blindness, cerebral ischemia or cerebral hemorrhage, leading to stroke, skin necrosis, damage to underlying facial structures, nausea and vomiting, lack of ocular movement, significant skin changes, ptosis, exotropia and neurological complications.

- Adverse events, other than mentioned above, could occur as can be with any medical intervention.

All (potential) adverse side effects and incidents should be reported immediately to the Sinclair Corporate Safety Group: quality@sinclair.com

For a full list of contraindications, warnings, and precautions for this product please visit http://www.sinclairpharma.com/eifu/ for a copy of the Product Instructions for Use.